ABFM Diabetes SAM Part 4

Similar documents
Joslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function

第十五章. Diabetes Mellitus

Diabetes Mellitus Type 2

Metabolic Syndrome and Chronic Kidney Disease

A Practical Approach to the Use of Diabetes Medications

Wayne Gravois, MD August 6, 2017

Application of the Diabetes Algorithm to a Patient

Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery

Clinical Cases in Diabetes Management. Joseph Cook D.O.

Type 2 Diabetes Mellitus Insulin Therapy 2012

Case Studies in T2DM A Comprehensive Management Approach

Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone

Type II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS

FUNDING: MICIS mandated by Maine Legislature, funded by fees collected from pharmaceutical companies as a cost of doing business in the state.

Physiology of Normoglycemia

The information in this guide comes from a government-funded review of research about pills for type 2 diabetes.

Adult Diabetes Clinician Guide NOVEMBER 2017

Complete this CE activity online at ProCE.com/InsulinPart2

Diabetes: Use of Adjunctive Therapy ACEs, ARBs, ASA & STATINs --Oh My! Veronica J. Brady, PhD, FNP-BC, BC-ADM, CDE Project ECHO April 19, 2018

Diabetes Mellitus II CPG

Diabetes Mellitus: Implications of New Clinical Trials and New Medications

Preventing Heart Attacks and Strokes Every Day (PHASE) RCHC Medication Titration Algorithm

AACN PCCN Review. Endocrine

Type 2 Diabetes Mellitus 2011

Medications for Type 2 Diabetes CDE Exam Preparation

Oral Medication for the Management of Diabetes Mechanism of. Duration of Daily Dosing Action

CURRENT ISSUES IN DIABETES MANAGEMENT. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test. Diagnosis of Diabetes 2013

CHALLENGING CASE PRESENTATION Steroid Induced Hyperglycemia

Endo 2 SLO Practice (online) Page 1 of 7

Intensification of Diabetic Therapy. Case studies

Antihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014

4/9/2018 HOW TO REGULATE DIABETES MEDICATIONS. By Sarah Froemsdorf MSN, RNC, CDE, FNP DISCLOSURES NONE. Diagnosis

Clinical Approach to Achieving Treatment Targets: Case Vignette Discussion

CURRENT CONTROVERSIES IN DIABETES CARE

Medications for Type 2 Diabetes CDE Exam Preparation. Wendy Graham, RD, CDE Mentor, WWD Angela Puim, RPh, CDE, CRE Preston Medical Pharmacy

Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes

Objectives. Kidney Complications With Diabetes. Case 10/21/2015

Diabetes Mellitus. Raja Nursing Instructor. Acknowledgement: Badil 09/03/2016

Disclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease

Diabetes Mellitus. Diabetes Mellitus : Diagnosis and Management. Etiologic Classification 7/9/2011

The Many Faces of T2DM in Long-term Care Facilities

Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy

Diabetes and New Meds for Cardiovascular Risk Reduction. F. Dwight Chrisman, MD, FACC. Disclosures: BI Boehringer Ingelheim speaker

Management of Diabetes Mellitus: A Primary Care Perspective

Diabetes and the Heart

Supplementary Appendix

Clinical Practice Guidelines

Type 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions

Glucose Control drug treatments

Management of Diabetes Mellitus: A Primary Care Perspective. Screening for Diabetes Advantages of HbA1c as a Diagnostic Test

In-Hospital Management of Diabetes. Dr Benjamin Schiff Assistant Professor McGill University

Patient With Implantable Cardiac Device (ICD)

Topic: Chronic Heart Failure Cases for Monday s March 21th lecture.

Diabetic Dyslipidemia

Diabetes Mellitus in Older Adults. Presenter Disclosure Information

DM Fundamentals Class 4 Meds for Type 2

I. General Considerations

Diabetes Complications Guideline Based Screening, Management, and Referral

Guidelines to assist General Practitioners in the Management of Type 2 Diabetes. April 2010

Philippine Practice Guidelines for the Diagnosis & Management of Type 2 Diabetes Mellitus

OBESITY IN TYPE 2 DIABETES

Julie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education

Management of Diabetes

Clinical Diabetes and Endocrinology in 2017 Pre and Post Test Questions

Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes!

Individualizing Care for Patients with Type 2 Diabetes

Non-Insulin Diabetes Medications Summary

Changing Diabetes: The time is now!

Application of the Diabetes Algorithm to Patients

Vipul Lakhani, MD Oregon Medical Group Endocrinology

Oral and Injectable Non-insulin Antihyperglycemic Agents

Prediabetes Prediabetes: You Can Help Your Patients Exit the Express Lane to Diabetes! Disclosures/Conflict of Interest.

No disclosures. Diabetes Test Topics. Case #1. Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan

Have participants measure their blood pressure daily at a standard time for two weeks. Obtain BP values from participant (fax, call, , mail).

The ABCs (A1C, BP and Cholesterol) of Diabetes

AACE/ACE Consensus Statement American Association of Clinical Endocrinologists and American College of Endocrinology

Learning Objectives. Outline 4/3/2018. Treatment Strategies to Maximize the Value of Diabetes Medications

CURRENT ISSUES IN DIABETES MANAGEMENT

Management of Type 2 Diabetes Mellitus. Heather Corn, MD, MS Endocrinology, Diabetes, and Metabolism

Diabetes Treatment Guidelines

Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October Your DM patient is ready for discharge, now what?

Hypertension, Hyperlipidemia and Obesity. Mi-CCSI

What s New in Diabetes Treatment. Disclosures

Non-insulin treatment in Type 1 DM Sang Yong Kim

Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control

egfr > 50 (n = 13,916)

SGLT2 Inhibitors

Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)

New Therapies for Diabetes

Diabetes Family Medicine Board Review

Managing Perioperative Diabetes What s new? Kathryn A. Myers MD FRCPC Chair Chief Division of GIM Professor of Medicine Western University

It Happens Even in Type 2! When to Start Thinking Seriously About Hypoglycemia

Quick Guide MEDICATIONS 7th Edition Evan Sisson, Pharm.D., MHA, CDE

Diabetes Mellitus Type 2

Prevention of MACROvascular Complications of Diabetes

Objectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors

Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials

7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine

Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes

HIHIM Clinical Cocepts for Managers 7/31/2009. Fernando Vega, MD 1

Transcription:

ABFM Diabetes SAM Part 4

37. A 55-year-old male with type 2 diabetes mellitus has a chronic history of reduced libido and erectile dysfunction. On examination you note hepatomegaly and mild testicular atrophy. You perform a non-fasting laboratory workup, with the following serum levels reported: Glucose.................. 250 mg/dl AST..................... 260 U/L (N 10 40) ALT..................... 210 U/L (N 10 55) FSH..................... 5.0 U/mL (N 1.0 12.0) LH...................... 8.1 U/mL (N 2.0 12.0) Testosterone.............. 180 ng/ml (N 280 1250) What is the most likely diagnosis? A) Glucagonoma B) Hemochromatosis C) Pheochromocytoma D) Acromegaly E) Cushing s syndrome

38. A 72 YO M sees you for a routine annual visit. PMH T2DM, CKD3, hyperlipidemia, TIA s/p CEA, and bladder cancer. Meds metformin 500 bid, sitagliptin 50 qd, nateglinide 120 tid ac, simvastatin 40 qd, ASA 81 qd. BP 134/76, BMI 28.2. Scattered AKs on forearms and absent pedal pulses Labs: Cr 1.9 (N0.6-1.5) EGFR 52 BUN 45 A1C 7.8 LDL 95 HDL 33 TGL 163 Which of the following would be appropriate at this time? (Mark all that are true) A) Increasing the dosage of simvastatin to 80 qd B) Starting basal insulin C) Starting niacin ER 500 qd D) Starting lisinopril 5 qd E) Starting pioglitazone 15 qd

39. A 60-year-old groundskeeper is brought to the emergency department unconscious. His temperature is 38.1 C (100.6 F) rectally, blood pressure 96/70 mm Hg, pulse 128 beats/min, and respirations 15/min. The examination is otherwise unremarkable except for very dry skin and mucous membranes. Laboratory Findings Serum sodium............. 150 mmol/l (N 135 145) Serum potassium........... 3.1 mmol/l (N 3.5 5.0) Serum chloride............. 112 mmol/l (N 100 108) CO2..................... 26 mmol/l (N 24 30) Serum glucose............. 1100 mg/dl Serum creatinine........... 4.0 mg/dl (N 0.6 1.5) BUN..................... 70 mg/dl (N 8 25) Serum ketones............. small amount present Which one of the following is the most likely diagnosis? A) Diabetic ketoacidosis B) Diabetes mellitus with lactic acidosis C) Diabetes mellitus with sepsis D) Hyperosmolar, hyperglycemic state E) Paraldehyde toxicity

40. A 71-year-old male with a history of type 2 diabetes mellitus and long-standing hypertension sees you because of worsening ankle edema, weight gain, and getting more winded when climbing stairs. His current medications are glipizide (Glucotrol), 10 mg/day; pioglitazone (Actos), 30 mg/day; extended-release metformin (Glucophage XR), 1000 mg/day; acarbose (Precose), 25 mg three times a day; lisinopril (Prinivil, Zestril), 40 mg/day; and hydrochlorothiazide, 12.5 mg/day. Which one of his medications is most likely responsible for his symptoms? A) Metformin B) Glipizide C) Pioglitazone D) Acarbose

41. Which one of the following types of insulin should never be mixed with any other form of insulin? A) Lente B) Ultralente C) Insulin glargine D) NPH E) Insulin lispro

42. Which one of the following oral agents is most likely to produce weight loss in the diabetic patient? A) Thiazolidinediones B) GLP-1-receptor agonists C) Sulfonylureas D) Metformin E) Alpha-glucosidase inhibitors

43. What is the minimum degree of weight loss recommended to reduce the risk of diabetes mellitus in a patient with impaired glucose tolerance? A) Weight reduction of 2% 4% B) Weight reduction of 5% 10% C) Weight reduction of 10% 20% D) Weight reduction of 20% 30% E) Achievement of ideal body weight

44. A 39-year-old female with type 2 diabetes mellitus develops microalbuminuria and is started on enalapril (Vasotec). At a follow-up visit 2 months later, an electrolyte panel reveals a normal serum creatinine level of 1.1 mg/dl, but her potassium level has risen from a baseline of 4.0 mmol/l to its present level of 5.4 mmol/l (N 3.5 5.0). Which one of the following is the most likely cause of her potassium elevation? A) Diabetic glomerulosclerosis B) Hyporeninemic hypoaldosteronism C) Hyperaldosteronism D) Hemolytic anemia E) Bilateral renal artery stenosis

45. A 42-year-old female with a body mass index (BMI) of 31 kg/m2 has a 3-week history of polyuria and polydipsia, accompanied by a 10-lb weight loss. Her fasting plasma glucose level is 320 mg/dl, and her hemoglobin A1c is 11.1%. Which one of the following is most likely to reverse her glucose toxicity and improve her glycemic response? A) Metformin (Glucophage) B) Pioglitazone (Actos) C) Glipizide (Glucotrol) D) Acarbose (Precose) E) Insulin

46. A 58-year-old female sees you for her annual checkup. Her past medical history is notable for a 15-year history of type 2 diabetes and hypercholesterolemia. Her current medications are extended-release metformin (Glucophage XR), 2000 mg/day; extended-release glipizide (Glucotrol XL), 5 mg/day; atorvastatin (Lipitor), 10 mg/day; and aspirin, 81 mg/day. The physical examination is unremarkable. The patient s blood pressure is 128/78 mm Hg and her BMI is 29.1 kg/m2. Laboratory testing reveals a hemoglobin A1C of 7.2%, an LDL-cholesterol level of 85 mg/dl, an HDL-cholesterol level of 36 mg/dl, and a serum triglyceride level of 190 mg/dl. The patient tells you that she plans to start jogging, and you order an exercise nuclear stress test which reveals findings suspicious for exercise induced ischemia. Coronary angiography reveals a 65% stenosis of the mid-right coronary artery. True statements regarding this situation include which of the following? (Mark all that are true.) A) The patient s aspirin dosage should be increased to 325 mg/day since it is now for secondary prevention B) The patient s atorvastatin dosage should be increased C) The patient s glipizide dosage should be increased D) Prompt revascularization has been shown to be superior to intensive medical therapy in terms of mortality and major cardiovascular events E) Percutaneous coronary intervention and coronary artery bypass graft surgery are equally effective in patients with diabetes mellitus and coronary heart disease

47. Patients must eat within 15 minutes of administration of which one of the following types of insulin? A) Lente B) Ultralente C) Insulin glargine D) NPH E) Insulin lispro

48. The United Kingdom Prospective Diabetes Study found which one of the following interventions to be most effective in reducing the risk of stroke and heart failure in diabetics? A) Good glycemic control B) Aggressive treatment of mild-to-moderate hypertension C) Aggressive treatment to lower triglyceride levels and raise HDL-cholesterol levels D) Aspirin therapy E) Use of an ACE inhibitor